ESMO CONGRESS 2022
Sep 09-13, 2022

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

List of Presentations

Pooled exploratory analysis of survival in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials

Yardley D

  • Presentation # 205P – Poster
    Sep 10, 2022 | Hall 4, 9:00 to 17:00 CEST (Display) | 12:00 to 13:00 CEST (Author presence)

This presentation will be available once the congress embargo lifts

HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-Enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)

Pascual T

  • Presentation # 272TiP – Poster
    Sep 10, 2022 | Hall 4, 9:00 to 17:00 CEST (Display) | 12:00 to 13:00 CEST (Author presence)

This presentation will be available once the congress embargo lifts

SOLTI-1911: Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive and HER2-negative breast cancer (RIBOLARIS)

Cottu P

  • Presentation # 203TiP – Poster
    Sep 10, 2022 | Hall 4, 9:00 to 17:00 CEST (Display) | 12:00 to 13:00 CEST (Author presence)

This presentation will be available once the congress embargo lifts

Decision-making criteria for the choice of 1st line CDK4/6-inhibitor therapy for HR+/Her2- breast cancer in Germany: DECISIONext

Finas D

  • Presentation # 233P – Poster
    Sep 10, 2022 | Hall 4, 9:00 to 17:00 CEST (Display) | 12:00 to 13:00 CEST (Author presence)

This presentation will be available once the congress embargo lifts

Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib

Tekpli X

  • Presentation # 1694P – Poster
    Sep 10, 2022 | Hall 4, 9:00 to 17:00 CEST (Display) | 12:00 to 13:00 CEST (Author presence)

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound